Retour aux projets

13952.1 PFLS-LS

13952.1 PFLS-LS

Résumé

MVX-ONCO-1: Encapsulation cell therapy for cancer immunotherapy: First in Man Clinical Study

Textes supplémentaires

Abstract

MaxiVAX SA, in collaboration with HUG and EPFL, has developed a novel, patient-specific, cell-based|immunotherapy, combining irradiated cancer cells and biocompatible capsules containing a cell line|producing a strong immune-stimulator. In May 2011, MaxiVAX¿ innovative immunization approach was|classified as an Advanced Therapeutic Product by the European Medicines Agency. The project is now|under regulatory review by SwissMedic and it expected that a first-in-man study in 15 patients can begin in|Q1-2012 with the infrastructure fully in place at the Cell Therapy Center at the HUG. This work provides an|essential milestone for the further validation development of effective novel anti-cancer therapies.

Participants

Nicolas Mach

Kontaktperson

nicolas.mach@hcuge.ch

HUG Hôpitaux Universitaires de Genève CHE-113.514.289 Nicolas Mach Rue Gabrielle-Perret-Gentil 4 1205 Genève GE CH

Clarence Peter

Wirtschaftspartner

cpeter@pplex.ch

MaxiVAX SA Clarence Peter Rue François Bellot 6 1206 Geneva GE CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2013-01-31
Date de fin
2015-07-31
Coûts totaux approuvés
CHF 150000.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T115 Medical technology 100.0%